Predictors of residual mass requiring surgical resection after chemotherapy of stage III testicular cancer. A prospective study.
In a prospective study, 63 patients with histopathologically proved Stage III nonseminomatous testicular cancer (NSTC) were analyzed to predict the need for surgical resection of residual masses after cis-platinum-based chemotherapy. Of these 63 patients, 23 (37%) had residual masses after cis-platinum-based chemotherapy requiring surgical resection. Of the 23 patients undergoing surgical resections for their residual masses, 18 patients (78%) had matured teratoma, 3 (13%) had fibrosis with necrosis, and 2 (9%) had residual tumors. Twenty of the 23 (91%) patients with residual disease had either teratomatous elements in primary tumor or bulky metastatic disease at the time of initial chemotherapy. Two patients had incomplete resection of the metastatic disease containing teratoma and required additional resection of recurrent growing matured teratomas. We conclude that teratomatous elements in primary tumor having also bulky metastatic disease are strong predictors of residual disease after initial chemotherapy requiring surgery (21 of 23 or 91%).
Javadpour
N
N
Division of Urology, Maryland General Hospital, University of Maryland, School of Medicine, Baltimore.
Young
J D
JD
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery*; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D013724:Teratoma / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery*; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery*
D002945:Cisplatin